Multiresistant gram negative bacilli. When consider them and how to treat them today
DOI:
https://doi.org/10.32818/reccmi.a5n1a17Keywords:
multidrug resistance, new drug approval, gram negative bacteria.Abstract
Infections due to multiresistant gram-negative bacilli are frequent and associated with elevated morbidity and mortality. It is important to recognize those patients at high risk. Its clinical management is complex, having witnessed important developments in recent years. Among these developments, we have new antibiotics, such as ceftolozane/tazobactam or ceftazidime/avibactam. We present a case of a 50 year-old man, with a recent liver transplant, that is admitted with pneumonia caused by multidrug-resistant Klebsiella pneumoniae, including carbapenemic resistance.
Downloads
Metrics
References
Karaiskos, Lagou, Pontikis, et al. The “old” and the “new” antibiotics for MDR gram-negative pathogens: for whom, when and how. Front. Public Health 7: 151. https://doi.org/10.3389/fpubh.2019.00151.
Rodríguez-Baño J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-San Francisco C, Gudiol C, et al.; Study Group of Nosocomial Infections (GEIH) of the Spanish Society of Infectious Diseases, Infectious Diseases (SEIMC). Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin. 2015; 33(5): 337.e1- 337.e21. https://doi.org/10.1016/j.eimc.2014.11.009.
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of in- fections caused by extended-spectrum-beta-lactamase, ampc-, and carbapene-mase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). pii: e00079-17. https://doi.org/10.1128/CMR.00079-17.
Koulenti D, Song A, Ellingboe A, Abdul-Aziz MH, Harris P, Gavey E, et al. Infections by multidrug-resistant Gram-negative bacteria: what's new in our arsenal and what's in the pipeline? Int J Antimicrob Agents. 2019; 53(3): 211-224. https://doi.org/10.1016/j.ijantimi-cag.2018.10.011.
Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs. 2019; 79(3): 271-289. https://doi.org/10.1007/s40265-019-1055-2.
Gutiérrez-Gutiérrez B, Salamanca E, de Cue- to M, Hsueh PR, Viale P, Paño-Pardo JR, et al.; REIPI/ESGBIS/INCREMENT Investigators. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017; 17(7): 726-734. https://doi.org/10.1016/S1473-3099(17)30228-1.
Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39(1): 10-39. https://doi.org/10.1002/phar.2209.
Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, et al. Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother. 2017; 61(4): pii: e02243-16. https://doi.org/10.1128/AAC.02243-16.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Jorge Calderón-Parra, Elena Muñez-Rubio, Ana Fernández-Cruz, Alejandro Callejas-Díaz, Antonio Ramos-Martínez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
